Shlomo Ben-Haim

Shlomo Ben-Haim is one of the more consequential figures in global medical device innovation, a physician and serial entrepreneur whose career includes founding Biosense, the cardiology mapping company that defined a generation of electrophysiology technology after its acquisition by Johnson and Johnson. His angel investing reflects that operating depth.

The thesis follows his clinical and technical heritage. The bulk of his angel activity concentrates on medical devices, with particular attention to cardiovascular care, advanced imaging and mapping, and the broader category of clinically grounded medical hardware. AI is increasingly relevant across his portfolio as machine learning intersects with device-generated data, signal processing, and procedural decision support. The unifying thread is conviction in companies where the technical foundation is genuinely deep and the clinical insight is grounded in real medical practice rather than market positioning.

Checks fall in the one to five million dollar range, which is large for an individual angel and reflects both his personal capacity and his willingness to take meaningful positions in companies he cares about. The stage range covers Pre-Seed, Seed, and Series A, with comfort in the kind of early-stage medical device companies where most institutional capital arrives later. Geography is centered on Israeli founders, with portfolio companies typically targeting global cardiovascular and medical device markets in the US and Europe. He is comfortable as a meaningful early backer who participates in subsequent rounds and provides continuity across the kind of multi-year arc that medical device companies require.

The value he brings is unusual. As a physician and successful serial entrepreneur, he understands medical device innovation from the standpoint of clinical practice, founder-operator experience, and the realities of building companies that exit to major medical device acquirers. His network reaches deep into global cardiovascular medicine, the major device companies, and the institutional investors who lead later rounds. Founders working with him get a partner whose judgment is calibrated across decades of medical device innovation rather than years of venture pattern matching.

In practice, the value-add concentrates on the parts of medical device company building that are genuinely hard. That includes clinical strategy, KOL development, regulatory and reimbursement pathway design, and the long-cycle work of building a company that survives the development timelines that medical device innovation actually requires. He is direct about scope. His engagement is highly selective and concentrates on companies where his clinical and technical heritage provides real leverage, primarily in cardiovascular care and adjacent medical hardware categories. For founders building cardiovascular and medical device companies with serious technical ambitions and credible clinical foundations, his backing is one of the more meaningful private endorsements available in the Israeli medical device ecosystem. The relationships he provides, the operating judgment he brings, and the patience he has for medical device timelines are difficult to find in any other single investor.